Joseph Catanzaro
Stock Analyst at Piper Sandler
(0)
# 4428
Out of 5,218 analysts
110
Total ratings
28.38%
Success rate
-11.12%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Cardiff Oncology | Maintains: Overweight | 7 10 | 3.87 | 158.4% | 4 | Dec 13, 2024 | |
Revolution Medicines | Maintains: Overweight | 57 70 | 44.99 | 55.59% | 2 | Nov 7, 2024 | |
Gilead Sciences | Maintains: Overweight | 95 105 | 91.85 | 14.32% | 4 | Nov 7, 2024 | |
Halozyme Therapeutic... | Maintains: Neutral | 51 52 | 47.98 | 8.38% | 7 | Nov 4, 2024 | |
ESSA Pharma | Downgrades: Neutral | 15 2 | 1.66 | 20.48% | 2 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 10 19 | 5.64 | 236.88% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 33 36 | 35.01 | 2.83% | 2 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 19 | 7.22 | 163.16% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 12 15 | 2.54 | 490.55% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 5 2 | 2.4 | -27.08% | 3 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 20 4 | 0.48 | 681.25% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 6 5 | 2.85 | 66.67% | 4 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 36 36 | 31 | 16.13% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 19 10 | 7.83 | 27.71% | 8 | Jul 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 40 40 | 12.72 | 214.47% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 15 15 | 8.67 | 73.01% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 35 35 | 20.21 | 73.18% | 1 | Jun 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Upgrades: Overweight | 3 4 | 1.08 | 224.07% | 3 | May 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 5 | 1.39 | 223.74% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 26 30 | 7.08 | 323.73% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 20 | 2.48 | 706.45% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 8 2 | 0.99 | 102.02% | 3 | Apr 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 105 | 18.83 | 457.62% | 2 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 15 10 | 0.96 | 941.67% | 4 | Mar 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 60 50 | 20.8 | 140.38% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 18 | 3.06 | 488.24% | 1 | Feb 12, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 10 | n/a | n/a | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 24 31 | n/a | n/a | 2 | Dec 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 30 25 | 1.76 | 1320.45% | 3 | Oct 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 58 | n/a | n/a | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 15 2 | n/a | n/a | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 18 20 | 21.36 | -6.37% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 15 11 | n/a | n/a | 1 | Nov 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 90 70 | n/a | n/a | 2 | Aug 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 25 2 | 1.11 | 35.14% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 12 10 | 0.43 | 2225.58% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 600 500 | n/a | n/a | 1 | Mar 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 35 | 6.06 | 477.56% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 60 | 4.06 | 1377.83% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 175 170 | n/a | n/a | 5 | Feb 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 55 60 | n/a | n/a | 3 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 18 | n/a | n/a | 2 | Jul 8, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 28 18 | 6.91 | 160.49% | 3 | Apr 7, 2020 |